◎ Sugi Atlas

Atlas / Drug / Bevacizumab

Bevacizumab

drug
On this page

Also known as AbevmyAbp-215AlymsysAVA-1AvastinAvziviAybintioBat 1706BAT-1706Bat1706Bevacizumab (avastin)Bevacizumab adcdBevacizumab awwbBevacizumab betaBevacizumab biosimilar (abp-215)Bevacizumab biosimilar (amgen)Bevacizumab biosimilar (ct-p16)Bevacizumab biosimilar (fkb-238)Bevacizumab biosimilar (gp-2019)

Summary

Bevacizumab (CHEMBL1201583) is an approved antibody (ATC L01FG01); indicated across 218 conditions including breast carcinoma and colorectal adenocarcinoma; with CIViC clinical evidence for 44 variant-indication associations (e.g. VEGFA Overexpression of VEGF121 and VEGF110 in breast cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FG01 (+1 more)
  • Indications: 218 conditions
  • Clinical trials: 2,295
  • Precision-oncology evidence (CIViC): 44 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201583
NameBevacizumab
TypeAntibody
Max phase4
ATCL01FG01, S01LA08

Also known as: Abevmy, Abp-215, Alymsys, AVA-1, Avastin, Avzivi, Aybintio, Bat 1706, BAT-1706, Bat1706, Bevacizumab, Bevacizumab (avastin)

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

218 indications (30 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast carcinoma4MONDO:0004989EFO:0000305
colorectal adenocarcinoma4MONDO:0005008EFO:0000365
glioblastoma4MONDO:0018177EFO:0000519
non-small cell lung carcinoma4MONDO:0005233EFO:0003060
renal cell carcinoma4MONDO:0005086EFO:0000681
neoplasm4MONDO:0005070EFO:0000616
ovarian carcinoma4MONDO:0005140EFO:0001075
cervical carcinoma4MONDO:0005131EFO:0001061
ovarian neoplasm4MONDO:0021068EFO:0003893
clear cell renal carcinoma4MONDO:0005005EFO:0000349
chromophobe renal cell carcinoma4MONDO:0017885EFO:0000335
papillary renal cell carcinoma4MONDO:0017884EFO:0000640
collecting duct carcinoma4MONDO:0005220EFO:0003016
breast neoplasm4MONDO:0021100EFO:0003869
colorectal neoplasm4MONDO:0005335EFO:0004142
peritoneal neoplasm4MONDO:0006901EFO:1001100
colorectal carcinoma4MONDO:0024331EFO:1001951
colonic neoplasm4MONDO:0005401EFO:0004288
fallopian tube carcinoma4MONDO:0006206EFO:1000251
fallopian tube neoplasm4MONDO:0021092MONDO:0002158
ovarian cancer4MONDO:0008170MONDO:0008170
cervical adenocarcinoma4MONDO:0005153EFO:0001416
ocular vascular disorder4MONDO:0005552EFO:0005753
age-related macular degeneration3MONDO:0005150EFO:0001365
brain neoplasm3MONDO:0021211EFO:0003833
diabetic retinopathy3MONDO:0005266EFO:0003770
exocrine pancreatic carcinoma3MONDO:0005192EFO:0002618
pterygium3MONDO:0005085EFO:0000678
retinal disorder3MONDO:0005283EFO:0003839
hepatocellular carcinoma3MONDO:0007256EFO:0000182
myopia3MONDO:0001384HP:0000545
prostate adenocarcinoma3MONDO:0005082EFO:0000673
corneal neovascularization3MONDO:0006713EFO:1000880
gliosarcoma3MONDO:0016681EFO:1001465
retinal vein occlusion3MONDO:0006951EFO:1001157
rectal cancer3MONDO:0006519EFO:1000657
retinopathy of prematurity3MONDO:0006952EFO:1001158
uveitis3MONDO:0020283EFO:1001231
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
gastric carcinoma3MONDO:0004950EFO:0000178
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
adenocarcinoma3MONDO:0004970EFO:0000228
mesothelioma3MONDO:0005065EFO:0000588
pancreatic neoplasm3MONDO:0021040EFO:0003860
retinal detachment3MONDO:0008375EFO:0005773
gastric adenocarcinoma3MONDO:0005036EFO:0000503
lung adenocarcinoma3MONDO:0005061EFO:0000571
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
wet macular degeneration3MONDO:0005417EFO:0004683
macular degeneration3MONDO:0003004EFO:0009606
colon adenocarcinoma3MONDO:0002271EFO:1001949
gastric neoplasm3MONDO:0021085MONDO:0001056
choroiditis3MONDO:0001280MONDO:0001280
telangiectasis3MONDO:0001576MONDO:0001576
brain cancer3MONDO:0001657MONDO:0001657
kidney cancer3MONDO:0002367MONDO:0002367
lung neoplasm3MONDO:0021117MONDO:0008903
rectal neoplasm3MONDO:0002165MONDO:0044937
follicular lymphoma3MONDO:0018906MONDO:0018906
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
malignant peritoneal mesothelioma3MONDO:0005512EFO:0005567
gastrointestinal stromal tumor3MONDO:0011719MONDO:0011719
Vogt-Koyanagi-Harada disease3MONDO:0018092MONDO:0018092
hereditary hemorrhagic telangiectasia3MONDO:0019180MONDO:0019180
glaucoma3MONDO:0005041MONDO:0005041
kidney neoplasm3MONDO:0021163EFO:0003865
paraganglioma3MONDO:0000448EFO:1000453
Coats disease3MONDO:0010269MONDO:0010269
choroidal neovascularization3MONDO:0810000MONDO:0810000
carcinoma2MONDO:0004993EFO:0000313
carcinoma of esophagus2MONDO:0019086EFO:0002916
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
central nervous system cancer2MONDO:0002714EFO:0000326
Kaposi’s sarcoma2MONDO:0005055EFO:0000558
upper aerodigestive tract neoplasm2MONDO:0005398EFO:0004284
myelodysplastic syndrome2MONDO:0018881EFO:0000198
metastatic melanoma2MONDO:0005191EFO:0002617
plasma cell myeloma2MONDO:0009693EFO:0001378
sarcoma2MONDO:0005089EFO:0000691
small cell lung carcinoma2MONDO:0008433EFO:0000702
germ cell tumor2MONDO:0005040EFO:0000514
keloid2MONDO:0005348EFO:0004212
carcinoid tumor2MONDO:0005369EFO:0004243
cutaneous melanoma2MONDO:0005012EFO:0000389
anterior ischemic optic neuropathy2MONDO:0006649EFO:1000809
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
Hodgkins lymphoma2MONDO:0004952EFO:0000183
alveolar rhabdomyosarcoma2MONDO:0009994EFO:0000248
astrocytoma (excluding glioblastoma)2MONDO:0019781EFO:0000272
chronic myeloid leukemia2MONDO:0011996EFO:0000339
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
leiomyosarcoma2MONDO:0005058EFO:0000564
leukemia2MONDO:0005059EFO:0000565
liposarcoma2MONDO:0005060EFO:0000569
lymphoma2MONDO:0005062EFO:0000574
neuroblastoma2MONDO:0005072EFO:0000621
oligoastrocytoma2MONDO:0016702EFO:0000630
oligodendroglioma2MONDO:0016695EFO:0000632
squamous cell carcinoma2MONDO:0005096EFO:0000707
melanoma2MONDO:0005105EFO:0000756
synovial sarcoma2MONDO:0010434EFO:0001376
fibrosarcoma2MONDO:0005164EFO:0002087
anaplastic astrocytoma2MONDO:0016684EFO:0002499
anaplastic oligodendroglioma2MONDO:0016696EFO:0002501
choriocarcinoma2MONDO:0005207EFO:0002893
rhabdomyosarcoma2MONDO:0005212EFO:0002918
medulloblastoma2MONDO:0007959EFO:0002939
lung large cell carcinoma2MONDO:0003050EFO:0003050
angiosarcoma2MONDO:0016982EFO:0003968
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
vascular disorder2MONDO:0005385EFO:0004264
cholangiocarcinoma2MONDO:0019087EFO:0005221
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
head and neck cancer2MONDO:0005627EFO:0006859
male breast carcinoma2MONDO:0005628EFO:0006861
ependymoma2MONDO:0016698EFO:1000028
pineoblastoma2MONDO:0016722EFO:1000475
thymoma2MONDO:0006456EFO:1000581
mantle cell lymphoma2MONDO:0018876EFO:1001469
endometrial carcinoma2MONDO:0002447EFO:1001512
soft tissue sarcoma2MONDO:0018078EFO:1001968
adenoma2MONDO:0004972EFO:0000232
endometrioid adenocarcinoma2MONDO:0005026EFO:0000466
undifferentiated carcinoma2MONDO:0005617EFO:0006772
pancreatic endocrine carcinoma2MONDO:0005893EFO:0007416
urothelial carcinoma2MONDO:0040679EFO:0008528
pulmonary fibrosis2MONDO:0002771EFO:0009448
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
somatostatinoma2MONDO:0006976EFO:1001187
neuroendocrine neoplasm2MONDO:0019496EFO:1001901
malignant peripheral nerve sheath tumor2MONDO:0017827EFO:0000760
pneumonia2MONDO:0005249EFO:0003106
central serous chorioretinopathy2MONDO:0018616EFO:0009784
diffuse intrinsic pontine glioma2MONDO:0006033EFO:1000026
central nervous system neoplasm2MONDO:0006130EFO:1000158
uterine carcinosarcoma2MONDO:0006485EFO:1000613
placental site trophoblastic tumor2MONDO:0020552EFO:1001111
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
papilloma2MONDO:0002363MONDO:0002363
benign fibrous histiocytoma2MONDO:0002989MONDO:0002989
glioma2MONDO:0021042MONDO:0003268
endometrium neoplasm2MONDO:0021251MONDO:0011962
nasal cavity and paranasal sinus lethal midline granuloma2MONDO:0006828MONDO:0019472
pancreatic insulinoma2MONDO:0024677MONDO:0024677
primary myelofibrosis2MONDO:0009692MONDO:0044903
clear cell adenocarcinoma2MONDO:0005004EFO:0000348
alveolar soft part sarcoma2MONDO:0011655EFO:0007143
thyroid gland carcinoma2MONDO:0015075EFO:0002892
intrahepatic cholangiocarcinoma2MONDO:0003210EFO:1001961
brain injury2MONDO:0043510MONDO:0043510
uterine corpus cancer2MONDO:0006003EFO:0007532
sex cord-stromal tumor2MONDO:0006055EFO:1000052
gallbladder neoplasm2MONDO:0021253MONDO:0005411
plasma cell neoplasm2MONDO:0004959EFO:0000200
pancreatic insulin-producing neuroendocrine tumor2MONDO:0005048EFO:0000549
osteosarcoma2MONDO:0009807EFO:0000637
squamous cell lung carcinoma2MONDO:0005097EFO:0000708
lymphoid leukemia2MONDO:0005402EFO:0004289
ocular melanoma2MONDO:0006325EFO:1000403
uveal melanoma2MONDO:0006486EFO:1000616
uterine cancer2MONDO:0002715MONDO:0002715
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
meningioma2MONDO:0016642MONDO:0020635
neuromyelitis optica1MONDO:0019100EFO:0004256
diabetic neuropathy1MONDO:0006626EFO:1000783
endometriosis1MONDO:0005133EFO:0001065
inflammatory breast carcinoma1MONDO:0006804EFO:1000984
cutaneous neuroendocrine carcinoma1MONDO:0019210EFO:1001471
ovarian serous cystadenocarcinoma1MONDO:0006046EFO:1000043
aseptic meningitis1MONDO:0006662EFO:1000823
pulmonary venoocclusive disease1MONDO:0009937MONDO:0009937
lymphedema1MONDO:0019297MONDO:0019297
acoustic neuroma1MONDO:0001569HP:0009588
pancreatic ductal adenocarcinoma1MONDO:0005184MONDO:0005184
cystic, mucinous, and serous neoplasm1MONDO:0006720MONDO:0037256
chronic kidney disease0MONDO:0005300EFO:0003884
pharynx cancer0MONDO:0005517EFO:0005577
desmoplastic small round cell tumor0MONDO:0019373EFO:1000895
von Hippel-Lindau disease0MONDO:0008667MONDO:0008667

38 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2,295.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 2,295 total).

PhaseTrials
PHASE21,023
PHASE3311
PHASE1/PHASE2157
PHASE462
PHASE2/PHASE347

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05185505PHASE4RECRUITINGAtezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05525767PHASE4RECRUITINGChemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
NCT06031233PHASE4RECRUITINGEvaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
NCT06121401PHASE4ACTIVE_NOT_RECRUITINGFirst Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT07014280PHASE4ACTIVE_NOT_RECRUITINGBevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.
NCT07059494PHASE4RECRUITINGAtezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
NCT07094893PHASE4NOT_YET_RECRUITINGAnti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status
NCT07358520PHASE4NOT_YET_RECRUITINGClinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
NCT00114946PHASE4TERMINATEDA Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00121836PHASE4COMPLETEDA Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
NCT00327093PHASE4TERMINATEDElaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT00451906PHASE4COMPLETEDA Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
NCT00468429PHASE4UNKNOWNSubconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery
NCT00496405PHASE4WITHDRAWNUnilateral Bevacizumab for Bilateral Diabetic Macular Edema
NCT00556348PHASE4COMPLETEDIntravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00557232PHASE4COMPLETEDIntraocular Bevacizumab (Avastin) for Rubeosis Iridis
NCT00566761PHASE4TERMINATEDTreatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO
NCT00577031PHASE4COMPLETEDOBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
NCT00682539PHASE4COMPLETEDIntraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
NCT00737971PHASE4COMPLETEDEfficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema
NCT00774241PHASE4WITHDRAWNPRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
NCT00797303PHASE4COMPLETEDThe Effect of Bevacizumab on Corneal Neovascularization
NCT00801866PHASE4WITHDRAWNAvastin for Post-photocoagulation Macular Edema
NCT00804206PHASE4TERMINATEDComparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation
NCT00805649PHASE4COMPLETEDCombined Therapy in Age-Related Macular Degeneration (ARMD)
NCT00815594PHASE4UNKNOWNBleb Vascularity Change After Subconjunctival Injection Bevacizumab
NCT01025934PHASE4COMPLETEDIntravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
NCT01085734PHASE4COMPLETEDSingle Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
NCT01094184PHASE4COMPLETEDA Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
NCT01127360PHASE4COMPLETEDLUCAS (Lucentis Compared to Avastin Study)
NCT01156961PHASE4WITHDRAWNA Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
NCT01166594PHASE4COMPLETEDUse of Bevacizumab in Trabeculectomy Surgery
NCT01229202PHASE4WITHDRAWNUse of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery
NCT01309451PHASE4COMPLETEDOzurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema
NCT01504724PHASE4COMPLETEDEffect of the Adjunctive IVB Before PRP
NCT01588184PHASE4COMPLETEDAn Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
NCT01588990PHASE4COMPLETEDA Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
NCT01695772PHASE4COMPLETEDA Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
NCT01706120PHASE4UNKNOWNStudy of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01736449PHASE4COMPLETEDRole of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Clinical evidence (CIViC)

Variant × indication × effect (44 predictive associations from 47 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
VEGFA Overexpression of VEGF121 and VEGF110Breast CancerSensitivity/ResponseBevacizumabCIViC BEID9299 +2
BRAF V600E AND BRAF AmplificationEpithelial Ovarian CancerSensitivity/ResponseAtezolizumab + BevacizumabCIViC BEID9885
EGFR Exon 18 OverexpressionLung Non-small Cell CarcinomaSensitivity/ResponseBevacizumab + ErlotinibCIViC BEID898
EGFR OverexpressionGlioblastomaSensitivity/ResponseLomustine + BevacizumabCIViC BEID10894
EGFR::WIF1 FusionIDH-wildtype GlioblastomaSensitivity/ResponseBevacizumabCIViC BEID11104
EMSY OverexpressionOvarian Serous CarcinomaSensitivity/ResponsePaclitaxel + Bevacizumab + CarboplatinCIViC BEID12149
FH DeficientHereditary Renal Cell CarcinomaSensitivity/ResponseBevacizumab + ErlotinibCIViC BEID12939
FH DeficientPapillary Renal Cell CarcinomaSensitivity/ResponseBevacizumab + ErlotinibCIViC BEID12940
IDH1 R132High Grade GliomaSensitivity/ResponseBevacizumab + SunitinibCIViC BEID2020
IDH1 R132High Grade GliomaSensitivity/ResponseBevacizumabCIViC BEID2330
IDH1 R132SHigh Grade GliomaSensitivity/ResponseBevacizumabCIViC BEID2339
MMP2 SERUM LEVELSInflammatory Breast CarcinomaSensitivity/ResponseBevacizumabCIViC BEID1156
MMP2 SERUM LEVELSBrain GliomaSensitivity/ResponseBevacizumabCIViC BEID1158
NF1 LossMalignant Peripheral Nerve Sheath TumorSensitivity/ResponseEverolimus + BevacizumabCIViC BEID7727
PPP1R15A RS557806Colorectal CancerSensitivity/ResponseFOLFIRI Regimen + BevacizumabCIViC BEID1325
VEGFA Decreased Peri-therapeutic ExpressionColorectal CancerSensitivity/ResponseLevoleucovorin + Irinotecan + Bevacizumab + FluorouracilCIViC BEID818
VEGFA OverexpressionGlioblastomaSensitivity/ResponseBevacizumabCIViC BEID7013
VEGFA OverexpressionStomach CancerSensitivity/ResponseBevacizumabCIViC BEID7216
VEGFA OverexpressionBreast CancerSensitivity/ResponseBevacizumabCIViC BEID9229
VEGFA Overexpression of VEGF121Her2-receptor Negative Breast CancerSensitivity/ResponseBevacizumabCIViC BEID9297
VEGFA Overexpression of VEGF121 and VEGF110Stomach CancerSensitivity/ResponseBevacizumabCIViC BEID9298
VEGFA low ratio of VEGF165b/VEGFtotalColorectal CancerSensitivity/ResponseBevacizumabCIViC BEID9358
VEGFA overexpression of VEGF-AxxxaBreast CancerSensitivity/ResponseBevacizumabCIViC BEID9290
BRAF MutationColorectal CancerResistanceBevacizumabCIViC BEID6305
BRAF V600EColorectal CancerResistanceBevacizumabCIViC BEID2120
BRAF V600EColorectal CancerResistanceBevacizumab + Capecitabine + OxaliplatinCIViC BEID2121
BRAF V600EColorectal CancerResistanceOxaliplatin + Capecitabine + Bevacizumab + CetuximabCIViC BEID8646
EPHB4 EXPRESSIONColorectal CancerResistanceBevacizumabCIViC BEID905
KRAS G12/G13Colorectal CancerResistanceBevacizumabCIViC BEID6295
KRAS MutationColorectal CancerResistanceBevacizumab + ChemotherapyCIViC BEID1139

+14 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem